U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 10 results

Status:
US Approved Rx (2018)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical. The drug was approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia...
Status:
US Approved Rx (2012)
First approved in 2003

Class (Stereo):
CHEMICAL (RACEMIC)



Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl e...
Status:
US Approved Rx (2013)
First approved in 1997

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a r...
Status:
US Approved Rx (2007)
First approved in 1995

Class (Stereo):
CHEMICAL (RACEMIC)



Carvedilol competitively blocks β1, β2 and α1 receptors. The drug lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through α1-blockade. Animal models indicate that carvedilol confers protection against myocard...
Status:
US Approved Rx (2017)
First approved in 1990

Class (Stereo):
CHEMICAL (RACEMIC)



Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms...
Status:
US Approved Rx (1998)
First approved in 1987

Class (Stereo):
CHEMICAL (RACEMIC)



Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate en...
Status:
US Approved Rx (2021)
First approved in 1976

Class (Stereo):
CHEMICAL (ACHIRAL)



Prazosin (trade names Minipress, Vasoflex, Lentopres, and Hypovase) is a selective α-1-adrenergic receptor antagonist used to treat hypertension. Prazosin acts by inhibiting the postsynaptic alpha-1-adrenoceptors on vascular smooth muscle. This inhib...
Status:
US Approved Rx (2017)
First approved in 1953

Class (Stereo):
CHEMICAL (RACEMIC)



Phenoxybenzamin (marketed under the trade name Dibenzyline) is an alpha-adrenergic antagonist with long duration of action. It is indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is exce...
Status:
US Approved Rx (2017)
First approved in 1952

Class (Stereo):
CHEMICAL (ACHIRAL)



Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking al...
Status:
US Previously Marketed
First approved in 1990

Class (Stereo):
CHEMICAL (ACHIRAL)



Dapiprazole is an alpha-1 adrenergic receptors antagonist which was developed for for the treatment of drug induced mydriasis produced by adrenergic or parasympatholytic agents. The drug was marketed under the name Rev-Eyes, however it was withdrawn ...